http://www.fpnotebook.com/

SotalolAka: Betapace

Indication
1. Ventricular Arrhythmia
2. Supraventricular Arrhythmia
  1. Atrial Fibrillation Cardioversion
    1. Time to Cardioversion: 3-6 hours
    2. Conversion Rate: 20-52%
    3. Chronic Efficacy: 50-60%
Mechanism
1. Class III Antiarrhythmic
  1. Prolongs action potential duration
  2. Increases cardiac tissue refractoriness
2. Class II Antiarrhythmic
  1. Non-selective Beta Blocker
Adverse Effects
1. Bradycardia
2. Hypotension
3. Proarrhythmia (Torsades de pointes)
  1. Associated with doses over 320 mg per day
Dosing: Oral
1. Starting Dose: 80 mg PO bid
2. Typical dosing: 80-160 mg PO bid
3. Maximum: 640 mg per day

Navigation Tree

Please see the Terms and Conditions. Please also see the privacy statement regarding advertising on this page. Although access to this page is not restricted, the information found here is intended for use by medical providers. Patients should address specific medical concerns with their physicians.

This page was written by Scott Moses, MD. This page was last revised on 4/26/2008 9:08:08 PM. This page was last published on 4/29/2008. Please send comments and questions to the editor. Contact information may be found on the page About the Family Practice Notebook. These pages are best viewed with Microsoft Internet Explorer 6.0.

Cardiovascular Medicine Book

Congestive Heart Failure

Coronary Artery Disease

Electrocardiogram

Examination

Hyperlipidemia

Hypertension

Miscellaneous

Pericardial Disorders

Obstetrics Chapter related topics

http://www.fpnotebook.com/

SotalolAka: Betapace

Navigation Tree